<p>This Adis Pocket Reference presents an up-to-date, succinct, and practical approach to drug therapy for type 2 diabetes.</p>
Changing Therapies in Type 2 Diabetes
โ Scribed by R.D.G. Leslie, Paolo Pozzilli
- Publisher
- CRC Press
- Year
- 2002
- Tongue
- English
- Leaves
- 112
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Synopsis
The Seventh International Barts Symposium was held on April 20, 2001, in London. This monograph summarizes the proceedings of that conference, which shed new light on therapies used for Type 2 diabetes. The contributors are world-renowned experts in the field, and they provide incisive commentary in their respective specialties. Chapters address new developments in the administration of insulin, including oral preparations and long-acting insulin analogue. Breakthroughs in the understanding of the pathogenesis of type 2 diabetes are also discussed, along with the future of the glitazones in management. Changing Therapies for Type 2 Diabetes is essential for diabetologists, general practitioners, cardiologists, geriatricians, and specialists in internal medicine.
๐ SIMILAR VOLUMES
This Adis Pocket Reference presents an up-to-date, succinct, and practical approach to drug therapy for type 2 diabetes.
<p>This concise handbook provides an overview of incretin-based therapies and guidance for incorporating them into the treatment of type 2 diabetes. Chapters include landmark clinical trials and international treatment guidelines in order to update readers with all major advances in the field. An id
<p>There is a world-wide epidemic on obesity. This epidemic is driving the immense proportions of Type 2 diabetes across the globe. While there are numerous therapies for treating Type 2 diabetes, the most effective therapy is prevention. Prevention of Type 2 diabetes can be achieved properly by sim
Adis, 2013. โ 107 p.<div class="bb-sep"></div>This book aims to provide an update on drugs available for the treatment of type 2 diabetes and where they fit within current treatment algorithms. The limited efficacy and tolerability of older drugs has spurred the development of several new classes of